The overall discrepancy in the efficacy of EZH2 inhibitors in lymphoma versus solid tumors, including TNBC in the context of primary tumor growth, is due to the lack of particular mutations (Y646, A682, and A692) in solid tumors that are present in lymphomas. Here, EZH2 is linked to lymphoma.